Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD20

CD20

Check out full-length Claudin 18.2, CD20 and more.

Brief Information

Name:B-lymphocyte antigen CD20
Target Synonym:B-lymphocyte surface antigen B1,MS4A1,B-lymphocyte antigen CD20,Membrane Spanning 4-Domains A1,Leukocyte Surface Antigen Leu-16,CD20 Antigen,CD20,Bp35,Membrane-Spanning 4-Domains Subfamily A Member 1,CD20 Receptor,LEU-16,CVID5,MS4A2,B1,S7,Antigens, CD20,Membrane-Spanning 4-Domains, Subfamily A, Member 1,B-Lymphocyte Cell-Surface Antigen B1
Number of Launched Drugs:30
Number of Drugs in Clinical Trials:96
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD0-HF2H5 Human FITC-Labeled Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc, SPR verified)
CD0-HF2H5-structure
CD0-HF2H5-sds
CD0-H52D5 Human Human CD20 / MS4A1 Full Length Protein, Flag,His Tag (Detergent)
CD0-H52D5-structure
CD0-H52D5-sds
HGS-S241 Mouse Recombinant Monoclonal Anti-CD20 Antibody, Mouse (6C8)
HGS-S260 Rabbit Recombinant Monoclonal Anti-CD20 Antibody, Rabbit (6G10)
CDP-HF2P8 Human Fluorescent Human CD20 Full Length Protein (VLP)
CD0-M36 Human Rituximab biosimilar–Research Grade
CD0-M36-sds
CHEK-ATP034 Human HEK293/Human CD20 Stable Cell Line
CD0-C52H5 Canine Canine CD20 / MS4A1 Full Length Protein, His Tag (Detergent)
CD0-C52H5-structure
CD0-C52H5-sds
CD0-C52H9 Canine Canine CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc)
CD0-C52H9-structure
CD0-C52H9-sds
CDP-H52P6 Human Human CD20 Full Length Protein (VLP)
CD0-C52H8 Cynomolgus Cynomolgus CD20 / MS4A1 Full Length Protein, His Tag (Detergent)
CD0-C52H8-structure
CD0-C52H8-sds
CD0-H52H1 Human Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc)
CD0-H52H1-structure
CD0-H52H1-sds
CD0-H82E3 Human Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Nanodisc)
CD0-H82E3-structure
CD0-H82E3-sds
CD0-H82E5 Human Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Detergent) (SPR verified)
CD0-H82E5-structure
CD0-H82E5-sds
CD0-H52H3 Human Human CD20 / MS4A1 Full Length Protein, His Tag (Detergent) (SPR verified)
CD0-H52H3-structure
CD0-H52H3-sds
ACRO Quality

Part of Bioactivity data

CD0-HF2H5-Cell-based assay
 CD20 FACS

Flow cytometric analysis of Anti-CD20 CAR-293 cells staining with FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) at 1 μg/mL (1 μg/mL corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with negative control protein. FITC signal was used to evaluate the binding activity (QC tested).

CHEK-ATP034-Cell-based assay
 CD20 FACS

FACS assay shows that Monoclonal Anti-Human CD20 Full Length Antibody, Human IgG1 can bind to HEK293/Human CD20 Stable Cell Line. HEK293/Human CD20 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

CD0-HF2H5-SPR
 CD20 SPR

Obinutuzumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 23.4 nM as determined in a SPR assay (Biacore 8K) (QC tested).

CD0-HF2H5-SPR
 CD20 SPR

Rituximab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 27.3 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Customer Reviews

Synonym Name

MS4A1,CD20,MS4A-1

Background

B-lymphocyte antigen CD20  is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mosunetuzumab RG-7828; BTCT-4465A; RO-7030816; CD20-TBD Approved Genentech Inc Lunsumio EU Lymphoma, Follicular Roche Registration Gmbh 2022-06-03 Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Ofatumumab OMB-157; HuMax-CD2; GSK-1841157; 2F2 Approved Genmab A/S Arzerra, Kesimpta United States Leukemia, Lymphocytic, Chronic, B-Cell Novartis Pharma Ag 2009-10-26 Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details
Rituximab biosimilar (CTTQ Pharma) TQB-2303 Approved Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Mainland China Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group 2023-05-26 Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma Details
Glofitamab RG-6026; RO-7082859; RG6026-2 Approved F. Hoffmann-La Roche Ltd COLUMVI, 高罗华 Canada Lymphoma, Large B-Cell, Diffuse F. Hoffmann-La Roche Ltd 2023-03-25 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details
Ripertamab SCT-400 Approved SinoCelltech Ltd Mainland China Lymphoma, Large B-Cell, Diffuse SinoCelltech Ltd 2022-08-23 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma Details
Ibritumomab tiuxetan IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA Approved Biogen Inc Zevalin, Zavalin United States Lymphoma, B-Cell Spectrum Pharmaceuticals Inc 2002-02-19 Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab IDEC-102; IDEC-C2B8; RO-452294; R-105; RG-105 Approved Biogen Inc MabThera, MabThera/Rituxan, 美罗华, Ristova, Rituxan United States Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell Genentech Inc, Idec Pharmaceuticals Corp 1997-11-26 Granulomatosis with Polyangiitis; Purpura, Thrombocytopenic, Idiopathic; Polymyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Peripheral Nervous System Diseases; Rejection of renal transplantation; Non-radiographic axial spondyloarthritis; Liver Cirrhosis, Biliary; Myasthenia Gravis; Diabetes Mellitus, Type 1; HIV Infections; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Leukemia; Opsoclonus-Myoclonus Syndrome; Ocular Motility Disorders; Keratoconjunctivitis Sicca; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Scleritis; ST Elevation Myocardial Infarction; Microscopic Polyangiitis; Rejection of liver transplantation; Renal Insufficiency; Dermatomyositis; Nephrosis; Myositis; Schizophrenia; Hemophilia A; Immunoglobulin G4-Related Disease; Pulmonary Alveolar Proteinosis; Stomach Neoplasms; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Arthritis, Rheumatoid; Kidney Diseases; P Details
Rituximab biosimilar (Reliance Life Sciences) R-TPR-017 Approved Reliance Life Sciences Toritz, RituxiRel India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid null 2016-01-01 Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Center of Molecular Immunology) Approved Center Of Molecular Immunology CIMAbior, RituxCIM Cuba Lymphoma, Non-Hodgkin null 2017-04-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Biocad) BCD-020 Approved Biocad Acellbia Russian Federation Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin Biocad 2015-01-01 Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Sandoz) GP-2013 Approved Sandoz Riximyo, Rixathon EU Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Pemphigus Sandoz Gmbh 2017-06-15 Lymphoma, B-Cell; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details
Rituximab biosimilar (Amgen) ABP-798; APB-798 Approved Amgen Inc Riabni United States Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin Amgen Inc 2020-12-17 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Philadelphia Chromosome; Lymphoproliferative Disorders; Leukemia, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Blast Crisis; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Microscopic Polyangiitis; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Candidiasis, Vulvovaginal; Lymphoma, B-Cell Details
Rituximab biosimilar (mAbxience) RTXM-83; mAbx-02 Approved Mabxience Sa Novex Argentina Lymphoma, Large B-Cell, Diffuse Mabxience Sa 2015-01-01 Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Anemia; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase Details
Rituximab biosimilar (Pfizer) PF-05280586; PF-5280586 Approved Pfizer Pharmaceuticals Ltd (China), Pfizer Inc Ruxience United States Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Granulomatosis with Polyangiitis; Microscopic Polyangiitis Pfizer Inc 2019-07-23 Lymphoma, Mantle-Cell; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Philadelphia Chromosome; Leukemia, B-Cell; Lymphoproliferative Disorders; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Granulomatosis with Polyangiitis; Richter's Syndrome; Lymphoma, Follicular; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, AIDS-Related; Leukemia, Lymphoid; Microscopic Polyangiitis; Anemia; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myelogenous, Chronic; Lymphoma, B-Cell Details
Ublituximab TG-1101; TGTX-1101; LFB-R603; TG-1303; EMAB-6; R-603 Approved Tg Therapeutics Inc Utuxin, BRIUMVI United States Multiple Sclerosis Tg Therapeutics Inc 2022-12-28 Multiple Sclerosis, Relapsing-Remitting; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Neuromyelitis Optica; Richter's Syndrome; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma Details
Ocrelizumab R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 Approved Genentech Inc Ocrevus United States Multiple Sclerosis Genentech Inc 2017-03-28 Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis Details
rituximab biosimilar (Zenotech) Approved Zenotech Laboratories India Lymphoma, Non-Hodgkin Zenotech Laboratories 2013-02-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (AryoGen Biopharma) Approved Aryogen Biopharma Zytux Iran Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis Aryogen Biopharma 2014-01-01 Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Zuberitamab HS-006 Approved Zhejiang Hisun Pharmaceutical Co Ltd 安瑞昔 Mainland China Lymphoma, Large B-Cell, Diffuse BioRay Pharmaceutical Co Ltd 2023-05-12 Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Thrombocytopenia Details
Rituximab biosimilar (Shanghai Henlius Biotech) HLX-01 Approved Shanghai Henlius Biotech Inc 汉利康 Mainland China Lymphoma, Non-Hodgkin Shanghai Henlius Biopharmaceuticals Co Ltd 2019-02-22 Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Obinutuzumab RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 Approved Genentech Inc Gazyva/Gazyvaro, Gazyva, Gazyvaro, 佳罗华 EU Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Roche Registration Gmbh 2014-07-22 Precursor Cell Lymphoblastic Leukemia-Lymphoma; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Nephrotic Syndrome; Lymphoproliferative Disorders; Glomerulosclerosis, Focal Segmental; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Glomerulonephritis, Membranous; Lupus Nephritis; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphoid; Nephrosis; Lymphoma, B-Cell; Leukemia Details
Rituximab biosimilar (Celltrion) CT-P10 Approved Celltrion Inc Truxima, Blitzima, Ritemvia, Rituzena EU Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis Celltrion Healthcare Hungary Kft 2017-02-17 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Blast Crisis; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Anemia; Microscopic Polyangiitis; Leukemia, Lymphoid; Granulomatosis with Polyangiitis; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase Details
Rituximab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Mabtas India Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Intas Biopharmaceuticals 2013-01-01 Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Biosidus) Approved Biosidus Argentina Hematologic Neoplasms Biosidus 2013-06-01 Hematologic Neoplasms Details
Epcoritamab GEN-3013; ABBV-GMAB-3013 Approved Genmab A/S, Abbvie Inc EPKINLY, TEPKINLY, Tepkinly United States Lymphoma, Large B-Cell, Diffuse Genmab Us Inc 2023-05-19 Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Hetero Drugs) Approved Hetero Drugs Ltd Maball, Mabura India Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Hetero Drugs Ltd 2015-01-01 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Innovent Biologics) IBI-301 Approved Innovent Biologics(Suzhou) Co Ltd 达伯华, HALPRYZA Mainland China Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Innovent Biologics(Suzhou) Co Ltd 2020-09-30 Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic Details
Rituximab biosimilar (Dr Reddy's Laboratories) Approved Dr.Reddy's Laboratories Ltd Tidecron, Reditux India Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Dr.Reddy's Laboratories Ltd 2007-01-01 Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Probiomed) PBO-326 Approved Probiomed Kikuzubam Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Hyaluronidase/Rituximab Approved Genentech Inc Rituxan Hycela United States Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular Genentech Inc 2017-06-22 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MRG001 MRG-001 Phase 1 Clinical Shanghai Miracogen Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) BAT-4306F Phase 1 Clinical Bio-Thera Solutions Ltd Lymphoma, Non-Hodgkin Details
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Lymphoma, Large B-Cell, Diffuse Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar(Bioxpress) BXT-2336 Clinical Bioxpress Therapeutics Sa Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell Details
bbT-369 bbT-369 Phase 2 Clinical Bluebird Bio Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Persongen Biotherapeutics Details
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) Phase 2 Clinical Shanghai Cellular Biopharmaceutical Group Ltd Lymphoma, B-Cell Details
Plamotamab XmAb-13676 Phase 1 Clinical Xencor Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Rituximab biosimilar (International Biotech Center Generium) GNR-006 Phase 1 Clinical International Biotech Center Generium Lymphoma, B-Cell Details
Rituximab biosimilar (Gedeon Richter) RGB-03 Phase 1 Clinical Gedeon Richter Arthritis, Rheumatoid Details
Rituximab biosimilar (Samsung) SAIT-101 Phase 3 Clinical Samsung Biologics Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Arthritis, Rheumatoid; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase Details
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center, National Cancer Institute Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin Details
Imvotamab IGM-2323 Phase 2 Clinical Igm Biosciences Inc Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Cutaneous; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lupus Erythematosus, Systemic; Arthritis; Lymphoma, Non-Hodgkin Details
Rituximab Biosimilar(Shanghai Institute Of Biological Products) SIBP-02 Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Prizloncabtagene autoleucel (AbelZeta Pharma) C-CAR039; C-CAR-039; C CAR 039; EXP-039 Phase 2 Clinical Cellular Biomedicine Group Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
MBS-303 MBS-303 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
ACE-1831 ACE-1831 Phase 1 Clinical Acepodia Biotech Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (JHL Biotech) JHL-1101 Phase 2 Clinical JHL Biotech Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
CHO-H01 CHO-H01 Phase 2 Clinical Academia Sinica Neoplasms; Lymphoma, Non-Hodgkin Details
MB-CART20.1 (Miltenyi Biotec) Phase 1 Clinical Miltenyi Biotec Melanoma Details
ICP-B02 CM-355; ICP-B02 Phase 2 Clinical Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin Details
TanCART19/20 Phase 1 Clinical Pla General Hospital Neuromyelitis Optica Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
UCART-20x22 UCART-20x22 Phase 2 Clinical Cellectis Sa Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Boehringer Ingelheim) BI-695500 Phase 3 Clinical C.H. Boehringer Sohn Ag & Co. Kg Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Pancytopenia; Plasmablastic Lymphoma; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Arthritis, Rheumatoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Anemia; Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic Details
Divozilimab BCD-132 Phase 3 Clinical Biocad Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica Details
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) CART-20; CBM-C20.1; CBM-CD20 1 Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jmt-Bio Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
BAT-4406F BAT-4406; BAT-4406F Phase 3 Clinical Bio-Thera Solutions Ltd Neuromyelitis Optica Details
Ocrelizumab biosimilar (Celltrion) CT-P53 Celltrion Inc Details
ADI-001 ADI-001 Phase 1 Clinical Adicet Bio Inc Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma Details
Bendamustine Hydrochloride/Rituximab Phase 1 Clinical 1globe Biomedical Co Ltd Lymphoma, B-Cell Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) B001 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Neuromyelitis Optica; Lymphoma, Non-Hodgkin; Lymphoma Details
ELC-301 ELC301; ELC-301 Phase 2 Clinical Elicera Therapeutics AB, Uppsala University Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) B-007 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar(Shandong New Time Pharmaceutical) H-02; F-007 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) PBCAR-20A Phase 2 Clinical Precision Biosciences Inc Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
TRS-005 TRS-005 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma, Non-Hodgkin Details
EX-103 EX-103; EX103 Phase 1 Clinical Guangzhou Excelmab Inc Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Hualan Biological Engineering) WBP-263 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical) CMAB-304 Phase 1 Clinical Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
CD20-directed CAR-T cell therapy (Tongji Hospital) C-CAR066 Phase 1 Clinical Tongji Hospital, Cellular Biomedicine Group Inc, Shanghai Cellular Biopharmaceutical Group Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Recombinant humanized monoclonal antibody MIL62 MIL62 Phase 3 Clinical Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Neuromyelitis Optica; Lymphoma, Non-Hodgkin Details
Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) Phase 1 Clinical Poseida Therapeutics Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma Details
ALETA-001 ALETA-001 Phase 2 Clinical Aleta BioTherapeutics Inc Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) Phase 2 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) Clinical Neoplasms Details
Ocrelizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Multiple Sclerosis Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma Details
IMM-0306 IMM-0306 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
TQB-2825 TQB-2825 Phase 1 Clinical Wuxi Biologics Co Ltd Hematologic Neoplasms Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Phase 1 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) TRS001 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma Details
IMPT-514 IMPT-514 Phase 2 Clinical ImmPACT Bio USA Inc Lupus Nephritis; Lupus Erythematosus, Systemic Details
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
RO-7121932 RO7121932; RO-7121932; RO 7121932; RG-6035 Phase 1 Clinical Genentech Inc Multiple Sclerosis Details
LY007 LY007 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
IMPT-314 IMPT-314 Phase 2 Clinical Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
Iodine 131 tositumomab TST/I131-TST Phase 3 Clinical Glaxosmithkline Plc Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
JS-203 JS-203 Phase 1 Clinical Shanghai Junshi Biological Engineering Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
1-A-46 BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 Phase 2 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) LZM-002 Phase 1 Clinical Livzon Pharmaceutical Group Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Genor Biopharma) GB-241 Phase 3 Clinical Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Blast Crisis; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Hematologic Neoplasms Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University, Shanghai YaKe Biotechnology Co Ltd Hematologic Neoplasms Details
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi Details
BVX20-CD20 antibody (Biocon/Vaccinex) BVX-20; BVX20-MAb Phase 2 Clinical Biocon Ltd, Vaccinex Inc Lymphoma, Non-Hodgkin Details
GB-261 GB-261 Phase 2 Clinical Genor Biopharma Co Ltd Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
LCAR-AIO LCAR-AIO; VHH CAR-T Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) Phase 1 Clinical National Cancer Institute Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD20 monoclonal antibody(The First Affiliated Hospital of Soochow University) Phase 2 Clinical The First Affiliated Hospital Of Soochow University Anemia, Aplastic Details
MB-106 MB-106 Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
QLP-31907 QLP-31907; QLP31907; PSB-202 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) LUCAR-20S Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
IPH-6501 IPH-6501; IPH-65 Phase 2 Clinical Innate Pharma SA Neoplasms; Lymphoma, Non-Hodgkin Details
Rituximab/Paclitaxel AR-160 Phase 1 Clinical Mayo Clinic Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab Biosimilar (Istituto Giannina Gaslini) Phase 2 Clinical Istituto Giannina Gaslini Nephrotic Syndrome Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message